TDAC
NASDAQ · N/A
Translational Development Ac
$10.52
+0.01 (+0.10%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 211.68M | 197.91M | 234.06M |
| Net Income | 7.59M | 7.31M | 8.97M |
| EPS | — | — | — |
| Profit Margin | 3.6% | 3.7% | 3.8% |
| Rev Growth | +3.0% | +7.4% | -1.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 13.11M | 13.88M | 13.83M |
| Total Equity | 149.77M | 147.03M | 146.13M |
| D/E Ratio | 0.09 | 0.09 | 0.09 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 13.67M | 12.28M | 15.52M |
| Free Cash Flow | 6.88M | 4.06M | 6.97M |